Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikatacho, Kita-ku, Okayama-city, Okayama, 700-8558, Japan.
Department of Hematology, Hokkaido University Hospital, Hokkaido, Japan.
Int J Hematol. 2020 Dec;112(6):871-877. doi: 10.1007/s12185-020-02967-x. Epub 2020 Aug 17.
Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.
实体器官移植(SOT)后的血液系统疾病随着长期 SOT 幸存者人数的增加而成为一个新出现的问题。需要有管理从独立供体接受异基因造血干细胞移植(HSCT)的 SOT 后患者的专业知识;然而,关于 SOT 后 HSCT 的临床报告有限,其可行性和风险尚不清楚。特别是,先前接受过肺移植的患者的 HSCT 被认为是复杂的,因为肺在免疫学上是不同的,并且不断暴露于周围环境中。在此,我们描述了一例先前因闭塞性细支气管炎综合征从已故供体接受肺移植的骨髓增生异常综合征患者成功接受 HSCT 的病例。关于肺移植后 HSCT 的病例报告非常罕见;因此,我们通过我们的病例的临床过程讨论了免疫耐受的机制。该病例表明,在移植器官功能保留且血液系统疾病缓解的情况下,SOT 后 HSCT 可以被视为一种治疗选择。